ストックスクリーナーアプリを入手
1.89
3.08%
-0.06
アフターアワーズ：
1.88
-0.01
-0.53%
前日終値:
$1.95
開ける：
$1.93
24時間の取引高:
889.27K
Relative Volume:
0.78
時価総額：
$435.32M
収益：
$8.95M
当期純損益:
$-21.49M
株価収益率:
-15.75
EPS:
-0.12
ネットキャッシュフロー:
$-29.24M
1週間 パフォーマンス:
+3.85%
1か月 パフォーマンス:
+7.39%
6か月 パフォーマンス:
+53.66%
1年 パフォーマンス:
+270.52%
1日の値動き範囲:
$1.865
$1.95
1週間の範囲:
$1.82
$1.985
52週間の値動き範囲:
$0.3651
$2.09
Lineage Cell Therapeutics Inc Stock (LCTX) Company Profile
名前
Lineage Cell Therapeutics Inc
セクター
電話
510-871-4188
住所
2173 Salk Avenue, Suite 200, Carlsbad, CA
Compare LCTX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LCTX
Lineage Cell Therapeutics Inc
|
1.89 | 449.14M | 8.95M | -21.49M | -29.24M | -0.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lineage Cell Therapeutics Inc Stock (LCTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-20 | 開始されました | Craig Hallum | Buy |
| 2022-11-02 | 開始されました | Robert W. Baird | Outperform |
| 2022-06-14 | 開始されました | B. Riley Securities | Buy |
| 2021-08-19 | 開始されました | Noble Capital Markets | Outperform |
| 2021-03-31 | 開始されました | Cantor Fitzgerald | Overweight |
Lineage Cell Therapeutics Inc (LCTX) 最新ニュース
LCTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is now the right time to enter Lineage Cell Therapeutics Inc2025 Top Decliners & Community Shared Stock Ideas - baoquankhu1.vn
Spinal Cord Injury Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals By DelveInsight | StemCyte, NervGen Pharma, VA Office of Research and Development - StreetInsider
LCTX PE Ratio & Valuation, Is LCTX Overvalued - Intellectia AI
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide - PharmiWeb.com
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026 - Business Wire
Institution Moves: How does Lineage Cell Therapeutics Inc compare to its peersJuly 2025 Momentum & Daily Technical Stock Forecast Reports - baoquankhu1.vn
CEO Moves: What are the future prospects of Lineage Cell Therapeutics IncDip Buying & Expert Curated Trade Setups - baoquankhu1.vn
Revenue Check: Is Lineage Cell Therapeutics Inc a top pick in the sectorWeekly Profit Summary & Weekly Market Pulse Alerts - baoquankhu1.vn
Will Lineage Cell Therapeutics Inc. stock keep raising dividendsMarket Performance Recap & Weekly High Conviction Trade Ideas - mfd.ru
Is Lineage Cell Therapeutics Inc. still a buy after recent gainsM&A Rumor & Reliable Entry Point Alerts - mfd.ru
LCTX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Will Lineage Cell Therapeutics Inc. stock hit new highs in YEAR2025 Investor Takeaways & Real-Time Volume Spike Alerts - mfd.ru
Is Lineage Cell Therapeutics Inc. a top pick in the sectorJuly 2025 Fed Impact & High Return Stock Watch Alerts - mfd.ru
Will Lineage Cell Therapeutics Inc. stock maintain dividend yieldMarket Sentiment Summary & Stepwise Trade Signal Implementation - mfd.ru
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Receives “Buy” Rating from D. Boral Capital - Defense World
D. Boral Capital Reiterates "Buy" Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) - MarketBeat
Lineage Cell Therapeutics (LCTX) Receives Consistent Buy Rating from D. Boral Capital | LCTX Stock News - GuruFocus
Lineage Cell says first OpRegen development milestone under Roche pact achieved - MSN
Progress In Research Spring 2024 - Christopher & Dana Reeve Foundation
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration - Investing News Network
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration - Benzinga
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Trading Down 3.1%Here's What Happened - MarketBeat
Spinal Cord Injury Market: Growth Momentum Across 7MM to 2034 – DelveInsight | Kringle Pharma, Neuroplast, Abbvie, Mitsubishi Tanabe Pharma, Lineage Cell Therapeutics, NervGen Pharma - Barchart.com
Hedge Fund Moves: Can Lineage Cell Therapeutics Inc maintain sales growth2025 Volatility Report & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
Trade Report: Is Lineage Cell Therapeutics Inc a top pick in the sectorRisk Management & Verified Entry Point Detection - baoquankhu1.vn
Market Moves: Is Lineage Cell Therapeutics Inc trading at a discountShare Buyback & Long-Term Safe Investment Plans - baoquankhu1.vn
What are the future prospects of Lineage Cell Therapeutics IncJuly 2025 Snapshot & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Guidance Update: Will Lineage Cell Therapeutics Inc stock hit new highs in YEARMarket Trend Review & Momentum Based Trading Signals - baoquankhu1.vn
Published on: 2026-01-25 17:25:52 - baoquankhu1.vn
Market Overview: Should I average down on Lineage Cell Therapeutics Inc stockEarnings Trend Report & Accurate Technical Buy Alerts - baoquankhu1.vn
Cell Therapy Manufacturing Market Set for Rapid Growth Through - openPR.com
Lineage Takes Delivery of Genetically Engineered iPSC Line with Hypoimmunity Edits from Factor Bioscience - BioInformant
Aug PostEarnings: Can Lineage Cell Therapeutics Inc stock outperform in 2025 bull market - Bộ Nội Vụ
Is Lineage Cell Therapeutics Inc. stock supported by innovation pipelineEarnings Performance Report & Scalable Portfolio Growth Methods - Улправда
CEO Moves: Why Lineage Cell Therapeutics Inc stock remains a top recommendationMarket Movers & Verified Momentum Stock Alerts - Bộ Nội Vụ
What dividend safety score for Lineage Cell Therapeutics Inc. stock2025 Geopolitical Influence & Safe Entry Point Alerts - ulpravda.ru
Aug Outlook: Is Lineage Cell Therapeutics Inc. stock among top earnings playsJuly 2025 Earnings & Comprehensive Market Scan Insights - ulpravda.ru
Institution Moves: How Lineage Cell Therapeutics Inc. stock trades during market volatility2025 Stock Rankings & Daily Stock Trend Reports - ulpravda.ru
Why Lineage Cell Therapeutics Inc. stock is a must watch in 2025July 2025 Breakouts & Safe Capital Growth Plans - Улправда
Is Lineage Cell Therapeutics Inc. stock among top earnings playsJuly 2025 Earnings & Comprehensive Market Scan Insights - ulpravda.ru
What dividend safety rating applies to Lineage Cell Therapeutics Inc. stock2025 Technical Overview & Target Return Focused Picks - Улправда
Can Lineage Cell Therapeutics Inc. stock resist sector downturnsEarnings Trend Report & Precise Swing Trade Alerts - ulpravda.ru
Will Lineage Cell Therapeutics Inc. stock deliver long term returnsTrade Signal Summary & Community Supported Trade Ideas - Улправда
Earnings Miss: Can Lineage Cell Therapeutics Inc. stock resist sector downturnsJuly 2025 Gainers & Reliable Entry Point Trade Alerts - ulpravda.ru
CEO Change: What dividend safety rating applies to Lineage Cell Therapeutics Inc. stock2025 AllTime Highs & Daily Stock Trend Reports - ulpravda.ru
D. Boral Capital Maintains Lineage Cell Therapeutics (LCTX) Buy Recommendation - MSN
Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock Price Up 7.6%What's Next? - MarketBeat
2026 world cup injury update tips: Will Lineage Cell Therapeutics Inc. stock benefit from sector rotation2026 world cup usa national team group stage goalkeepers transition play group prediction guide - ulpravda.ru
Lineage Cell Therapeutics (LCTX) Advances Stem Cell Collaboratio - GuruFocus
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience - Business Wire
Lineage Cell Therapeutics Inc (LCTX) 財務データ
収益
当期純利益
現金流量
EPS
5.71%
0.02%
大文字化:
|
ボリューム (24 時間):